Abstract: This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Abstract: The invention provides a drug conjugate comprising: 1) a therapeutic agent that comprises a phosphate, phosphonate, carboxy, or phosphoramidate group, and 2) a fluorescent group linked to the phosphate, phosphonate, carboxy, or phosphoramidate group to form the corresponding ester and salts thereof. The conjugates are useful for therapy and as probes. The invention also provides therapeutic methods for treating diseases with conjugates of the invention as well as methods for determining optimal dosages of a conjugate or a therapeutic agent for a given patient using a conjugate of the invention.

Abstract: The invention provides a water purification system or a water treatment system comprising carbon nanotubes, as well as methods for purifying or treating water using the systems of the invention.

Abstract: Composites comprising polymeric nanofibers, metal oxide nanoparticles, and optional surface-segregating surfactants and precursor compositions are disclosed. Also disclosed are nonwoven mats formed from the composites and methods of making and using the composites. The composites enable the deployment of nanostructured materials for water treatment within a self-contained membrane with high water fluxes, as well as a number uses.

Abstract: The invention provides an isolated chimeric virus comprising bocavirus capsid protein and a recombinant adeno-associated viral (AAV) genome, an isolated rBoV comprising human bocavirus capsid protein and a recombinant BoV genome, and uses therefor. For example, the chimeric virus may be employed to deliver transgenes, such as those encoding therapeutic or prophylactic gene products, to mammalian cells.

Abstract: The invention provides a compound of formula (Ia) or (Ib): or a salt thereof, wherein A, B, C, D, E, F, J, K, L, M, Q, V, X, Y, W and Z have any of the values described in the specification, as well as compositions comprising a compound of formula (Ia) or (Ib) or a salt thereof, and methods of use thereof.

Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.

Abstract: Disclosed are systems and methods for image segmentation using convolutional networks. Image data comprising an image hypervolume can be received. The image hypervolume can be provided to a trained convolutional neural network (CNN). The CNN can output a segmentation of the image hypervolume.

Abstract: In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, and anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof.

Abstract: The present invention relates to a rapid detection of microbial-associated nuclease activity with chemically modified nuclease (e.g., endonuclease) substrates, and probes and compositions useful in detection assays.

Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.

Abstract: Methods for isolating viable cancer cells from a sample that comprises a mixture of cancerous cells and normal (non-cancerous) cells are provided. In the methods, a fluid preparation comprising a mixture of cancerous and normal cells is repeatedly exposed to fluid shear stresses, whereby the repeated exposure to the fluid shear stresses preferentially imparts fluid shear stress-resistance to the cancerous cells.

Abstract: Embodiments of the present invention comprises apparatuses and methods of measuring levels of neurological impairment. Certain embodiments of the invention comprise a headset that emits light into the user's eyes and the system tracks the pupils' orientation, movement, contraction and dilation. In specific embodiments, the headset can run a battery of tests and calculate a score indicating the user's level of neurological impairment.

Abstract: According to various embodiments, a system for forming a ceramic part includes a chamber having a first closed end and a second end defining an opening. The platform is disposed within the chamber and adapted to move vertically in a z-direction between the first closed end and the second end. An applicator is adapted to move laterally in an x-y direction. The applicator includes a beveled edge. A light source is positioned in line with the second end of the chamber. A digital micro-mirror device is positioned between the light source and the second end of the chamber. The shutter is movable between a first open position and a second open position. A first image is projected when the digital micro-mirror device is in the first open position and a second image, different than the first image is projected when the digital micro-mirror device is in the second open position.

Abstract: The invention provides a compound of formula (I): or a salt thereof, wherein R1 and R2 have any of the values defined in the specification, as well as methods of using such compounds and salts to separate an aryl compound from a mixture.

Abstract: In certain embodiments, the present invention provides a detection composition comprising a picodroplet comprising (a) an aqueous solution, and (b) a substrate probe comprising (i) an oligonucleotide of 2 to 75 nucleotides in length, (ii) a fluorophore operably linked to the oligonucleotide, and (iii) a quencher operably linked to the oligonucleotide. As used herein, the term “picodroplet” comprises a liquid droplet that has a volume of 0.014 to 2.6 picoliters.

Abstract: In certain embodiments the present invention provides a method of treating hearing loss comprising: (a) administering a gene suppression agent that suppresses both copies of an endogenous gene causing the hearing loss; and (b) administering an exogenous wild-type allele engineered to resist suppression by the gene suppression agent. The present invention provides in certain embodiments a method of treating a genetic hearing loss (GHL) in a patient in need thereof comprising: (a) identifying a mutation in a GHL-causing gene, wherein the mutation causes GHL in the patient; and (b) administering to the patient a pharmaceutical composition comprising a therapeutic miRNA and a pharmaceutically acceptable carrier, wherein the GHL therapeutic miRNA is of 18 to 25 nucleotides in length and knocks-down the GHL-causing gene function at a higher level than it knocks-down gene function in a corresponding wild-type gene.

Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof and an anti-cancer composition.

Abstract: A fluid handling system for applying a plurality of pulses of fluid shear stress to a fluid sample may comprise a first sample chamber; a second sample chamber; a plurality of conduits mounted between and in fluid communication with the first sample chamber and the second sample chamber; and a force delivery system mounted to the first sample chamber and configured to apply a force sufficient to push the fluid sample from the first sample chamber through each of the conduits at a substantially constant flow rate to the second sample chamber. The plurality of conduits may be arranged in series and separated by additional sample chambers or arranged such that the conduits are substantially parallel to one another. The force delivery system may be a gas delivery system or a linear drive assembly.

Abstract: In certain embodiments, the present invention provides the use of microRNA (miR)-200a to inhibit ossification and bone formation.